Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation (NCT03842696)
A Phase 1/2 Multi-Center Trial of Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine the recommended phase 2 dose of the drug Vorinostat in children, adolescents and young adults following allogeneic blood or marrow transplant (BMT) and determine whether the addition of Vorinostat to the standard graft versus host disease (GVHD) prophylaxis will reduce the incidence of GVHD.
Who can join: Review the eligibility criteria below.
Location: University of Colorado — Aurora, Colorado
Age range: 3 Years to 39 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- University of Colorado — Aurora, Colorado
- Emory University — Atlanta, Georgia
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
- University of Michigan Health System — Ann Arbor, Michigan
- Henry Ford Hospital — Detroit, Michigan
- Vanderbilt-Ingram Cancer Center — Nashville, Tennessee
- Medical College of Wisconsin — Milwaukee, Wisconsin
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hematologic Diseases
- Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies — Buffalo, New York
- The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research — San Diego, California
- Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback — Palo Alto, California
- The Interplay Between Inborn Error of Immunity and Blood Disorders: Unravelling Immune Defects Behind Common Haematological Diseases — Montreal, Canada
- Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults — Palo Alto, California
Explore by condition: All Hematologic Diseases clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.